Statement: the primary trial studies the impact of Fulvestrant, Docetaxel on Oestrogen Receptor H-score.
Primary_evidence: Outcome Measurement:    Percentage Change From Baseline to Time of Surgery in Oestrogen Receptor (ER) H-score: Antitumour Effects of Fulvestrant, Anastrozole and a Combination of Both as Measured by the ER H-score.   For each sample, the ER H-score is calculated from the percentage of cells staining very weak (+/-); weak (+); moderate (++); or strong (+++) as follows: H-score = [(0.5 x percent +/-) + (1 x percent +) + (2 x percent ++) + (3 x percent +++)]. Range 0-300. The greater the change from baseline (randomization) in ER H-score, the greater the blockage of ER expression and the greater the potential anti-tumour activity. Percentage change from baseline=[(SRG - BL)/BL]x100   Time frame: Surgery (SRG) was to be performed between days 15 and 22 after baseline (BL) Results 1:    Arm/Group Title: Fulvestrant   Arm/Group Description: Fulvestrant 500 mg once monthly injection   Overall Number of Participants Analyzed: 35   Mean (Standard Error)   Unit of Measure: Percentage change from baseline  -37         (4) Results 2:    Arm/Group Title: Fulvestrant + Anastrozole   Arm/Group Description: Fulvestrant 500 mg once monthly injection + Anastrozole 1 mg once daily tablet   Overall Number of Participants Analyzed: 31   Mean (Standard Error)   Unit of Measure: Percentage change from baseline  -38         (5)